EUCTR2007-000903-14-GB
Active, not recruiting
Not Applicable
Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer. - Neostat
Conditionson-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10025050Term: Lung cancer non-small cell stage IMedDRA version: 9.1Level: LLTClassification code 10025051Term: Lung cancer non-small cell stage IIMedDRA version: 9.1Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage IIIMedDRA version: 9.1Level: LLTClassification code 10025053Term: Lung cancer non-small cell stage IIIA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer
- Sponsor
- Imperial College, London
- Enrollment
- 184
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological or cytological confirmed NSCLC or sufficiently strong clinical evidence to justify thoracotomy.
- •Stage I\-IIIA disease that is suitable for surgical resection.
- •Surgery planned between 14 and 42 days after registration.
- •Serum Creatinine concentration \<1\.5 times the upper limit of normal. (ULN)
- •Aged 18 or over.
- •Written informed consent prior to admission to this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •Prior chemotherapy or radiotherapy for this disease.
- •Patients treated with statins within 1 year prior to randomization.
- •Active liver disease or unexplained elevation of AST and/or ALT \>2\.5xULN.
- •Creatinine Kinase \>5xULN.
- •Concomitant use of: CYPA4 inhibitors such as cyclosporine, itraconazole, ketoconazole, erythroymicin, clarithromycin,HIV protease inhibitors, jefazodone, or larg quantities of grapefruit juice (\>250ml/day)
- •Lipid\-lowering drugs that can cause myopathy such as gemifibrozil, other fibrates, or lipid\-lowering doses (\>1g/day) of niacin.
- •Amiodarone or verapamil.
- •Hypersensitivity to lovastatin or pravastatin or any of their excipients.
- •Evidence of significant mediacal condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial.
- •Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocytic Leukemia'Second line therapy with fludara plus Alentuzumab (Mabcampath) in Patient with b-cell Chronic Lymphocytic LeukemiaMedDRA version: 14.1Level: PTClassification code 10008962Term: Chronic lymphocytic leukaemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2004-000149-39-ITGenzyme Corporation300
Completed
Phase 3
Improving vision to prevent falls: a randomized trialAccidental fallsInjuries and Accidents - Other injuries and accidentsACTRN12605000144617niversity of Sydney800
Not yet recruiting
Not Applicable
Tauranga Older Persons Comprehensive Assessment TrialACTRN12606000042549Ministry of Health, New Zealand320
Recruiting
Phase 3
Early inpatient-outpatient hospital-based pulmonary rehabilitation following hospitalisation for acute exacerbations of COPD: a randomised controlled studyChronic Obstructive Pulmonary Disease (COPD)Respiratory - Chronic obstructive pulmonary diseasePhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12605000372684Green Lane Research and Educational Fund100
Active, not recruiting
Phase 1
A trial of oral azacitidine compared to standard treatment in patients with relapsed lymphoma.Relapsed or Refractory Angioimmunoblastic T cell LymphomaMedDRA version: 21.1Level: PTClassification code 10002449Term: Angioimmunoblastic T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003909-17-GBYSARC: THE LYMPHOMA ACADEMIC RESEARCH ORGANISATIO